Compound ID | 1252
RX-P2382
Class: Small molecule antibacterial agent
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Protein synthesis inhibitor |
| Target Pathogen: | Active against multidrug-resistant ESKAPE pathogens known to cause complicated urinary tract, skin, and lung infections, and sepsis |
| Description: | A pyrrolocytosine |
| Institute where first reported: | Melinta Therapeutics, Inc |
| Year first mentioned: | 2018 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| Citation: | https://www.jmilabs.com/data/posters/ASM-ESCMID-2018-RX-P2382-ribosome-inhibitor.pdf |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.